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This thesis is presented as one paper prepared for the submission to the Journal of 
Dairy Science from research performed to partly fulfill the requirements for a Master of 
Science degree. The paper is complete in itself including an abstract, introduction, materials 
and methods, results, discussion, conclusions, and references. A title of the paper is 
"Prevention of fatty liver in transition dairy cows by 14-day subcutaneous glucagon 
injections". The data from the paper indicate the potential use of a peptide hormone glucagon 
for fatty liver prevention in transition dairy cows. The paper is preceded by a literature 
review and followed by general conclusions containing a general discussion and 
recommendations for future research sections. References conclude the thesis. 
Literature Review 
Introduction. 
Fatty liver (hepatic lipidosis) is a metabolic disorder of dairy cows that occurs 
generally during the first two weeks of lactation and is characterized by excessive lipid 
accumulation in the liver. However, cows can develop fatty liver at any other time during 
2 
lactation because of many different reasons. The prevalence of fatty liver can be up to 54% 
of a dairy herd (Jorritsma et al., 2000a), and the morbidity and mortality from this syndrome 
may reach 90 and 25%, respectively (Raoofi et al., 2001). The consequences of fatty liver 
development in dairy cows can be attributed to their reduced productivity, reproductive 
performance, suppressed immunity, and increased susceptibility to different infectious and 
metabolic diseases (Bremmer et al., 2000; Jorritsma et al., 2000a; Raoofi et al., 2001). In 
particular, cows prone to fatty liver can develop ketosis, milk fever, udder edema, displaced 
abomasum, retained fetal membranes, metritis, and mastitis (Drackley, 1999; Katoh, 2002; 
Morrow, 1976; Van Winden et al., 2003). Metabolic disorders such as fatty liver, milk fever, 
and ketosis tend to occur in complexes and probably could have some general cause. 
Accumulation of high amounts of triacylglycerols (TAG) by liver of lactating dairy cows is 
highly correlated with their decreased fertility and an increase in the interval from parturition 
to first ovulation (Jorritsma et al., 2000b; Rukkwamsuk et al., 1999b). Fatty liver 
development during the first two weeks postpartum is associated with decreased functional 
capacities of polymorphonuclear neutrophilic granulocytes derived from blood and uterus, 
which may be why cows with fatty liver have a higher incidence of infectious diseases such 
as endometritis (Zerbe et al., 2000). 
Etiology of Fatty Liver Disease. 
Dairy cows after parturition are in a negative energy balance (NEB) state. This means 
that their feed intake and body reserves cannot supply enough energy and nutrients for 
maintenance and milk production. With the onset of lactation, cows have increased 
requirements for glucose production, which is used as a fuel and for lactose biosynthesis. 
3 
High demands for glucose in dairy cows at the beginning of lactation exacerbate the energy 
deficit. One of the reasons for cows not being able to meet their energy needs is a decline in 
their feed intake a few days before calving. After parturition, feed intake of dairy cows rises 
much slower than their energy needs. 
To meet their energy and glucose production needs, cows mobilize TAG from 
adipose tissue and use nonesterified fatty acids (NEFA) as a primary energy source. Thereby, 
they can repartition glucose towards lactose biosynthesis. For some reasons, cows in a NEB 
mobilize more TAG than they can utilize, which leads to an increased blood NEF A 
concentration. A high blood NEF A concentration is considered to be one of the major risk 
factors for the development of fatty liver disease (Herdt, 1988). 
In liver, NEFA can undergo mitochondrial (Figure 1) or peroxisomal ~-oxidation to 
acetyl-CoA, which is oxidized to carbon dioxide in the citric acid cycle with concomitant 
ATP production or uncoupling of oxidative phosphorylation and production of reactive 
oxygen species (ROS). Alternatively, NEFA can undergo incomplete oxidation with 
production of ketone bodies. In addition, NEFA can be esterified into TAG and stored in the 
liver. Triacylglycerols can be used for production of very low density lipoproteins (VLDL), 
which are secreted into the blood stream (Gruffat et al., 1996). An imbalance between 
complete and incomplete NEF A oxidation, production and secretion of VLDL, and TAG 
formation and storage in liver can lead to the development of hepatic steatosis. 
High blood NEFA concentration in dairy cows is highly correlated with fatty liver 
development postpartum. The hepatic uptake of NEF A depends on its concentration in blood 
and the rate of blood flow to the liver (Gruffat et al., 1996). Therefore, higher blood NEFA 

























































































































































































































to have a relatively low capacity for production and secretion of VLDL from the liver 
(Hocquette and Bauchart, 1999). So, the inability of liver to oxidize all NEPA that enters it 
and impaired production and/or secretion of VLDL can lead to TAG accumulation and fatty 
liver development. 
Impairment in production and secretion of VLDL by the liver is considered as one of 
the factors that contributs to the development of fatty Ii ver disease postpartum in dairy cows 
(Bremmer et al., 2000; Katoh, 2002). The rate of liver TAG synthesis in ruminants and 
nonrurninants is similar, but the rate of their secretion via VLDL is much slower in ruminants 
than in nonruminants (Bremmer et al., 2000; Pullen et al., 1990). A possible explanation for 
this could be the fact that ruminants, unlike nonruminants, use adipose tissue as a major site 
for fatty acid synthesis, and as such, they do not need to have as good a mechanism for TAG 
secretion from the liver (Katoh, 2002). 
Cows with fatty liver disease have reduced VLDL secretion (Rayssiguier et al., 1988) 
by the liver. Reduction in the secretion of VLDL from cows with fatty liver was attributed to 
lower concentrations of apolipoprotein B-100 (apoB-100), which is a TAG-binding protein 
that required for assembly of VLDL particles (Pullen et al., 1990; Yamamoto et al., 1995). 
The apoB-100 rnRNA concentration in liver does not decrease substantially during earlier 
stage of lactation, which indicates that apoB-100 concentration may be regulated 
posttranslationally by proteolytic degradation of apoB-100 protein (Gruffat et al., 1997). The 
reasons for increased proteolytic degradation of apoB-100 postpartum are not known. 
Because of the high correlation between elevated blood NEPA concentration and 
fatty liver development in transition dairy cows (Herdt et al., 1988), there have been several 
attempts to relate the fatty acid composition of liver, blood NEPA, and adipose tissue to the 
6 
etiology of fatty liver development (Rukkwamsuk et al., 2000; Sato et al., 2004). Cows with 
fatty liver disease had higher concentrations of palmitic, oleic, linoleic, but not stearic acid, 
in liver. However, the composition of fatty acids in adipose tissue was the same in healthy 
and fatty liver cows before and after parturition (Rukkwamsuk et al., 2000). Palmitic, stearic, 
and oleic acids were the major fatty acids found in adipose tissue and blood. Different 
feeding strategies (feed restriction or overfeeding) did not affect fatty acid composition in 
adipose tissue and plasma. 
Hepatic steatosis occurs in two forms: microvesicular and macrovesicular (Haque and 
Sanyal, 2002). Microvesicular steatosis is characterized by cytoplasmic accumulation of 
numerous small, fat-filled, globules that do not cause displacement of the nucleus. This 
condition is associated with disorders of the urea cycle, which results in mitochondrial 
abnormalities and hyperammonemia. Macrovesicular steatosis is characterized by 
cytoplasmic accumulation of one or two large globules of fat, which causes displacement of 
the nucleus to the periphery of the hepatocyte. 
Even though there is a lack of the information about histopathological studies of fatty 
liver cases in dairy cows, at least mild fatty liver in dairy cows could be characterized as a 
microvesicular steatosis. This assumption is supported by data indicating that cows with fatty 
liver could have mitochondrial dysfunction and suppressed ureagenesis (Hocquette and 
Bauchart, 1999; Reid and Collins, 1980; Strang et al., 1998). However, severe fatty liver in 
dairy cows could be an example of macrovesicular steatosis, which can develop into 
steatohepatitis and/or fibrosis with the possible progression of fibrosis into cirrhosis. 
It is obvious that fatty liver itself is not just an innocent lipid accumulation. Two main 
pathways of liver injury are considered to be responsible for the pathogenesis of fatty liver-
7 
oxidative stress-induced lipid peroxidation and cytokine-mediated injury (Day, 2002). 
According to the "two-hit" hypothesis (Figure 2), high blood NEPA concentration can cause 
steatosis (lipid accumulation by liver), which is "the first hit". Then, steatosis itself makes 






The first 'hit' 
t Peroxidation 
t Sensitivity to 
TNF-a 
Figure 2. The 'two hits' hypothesis of nonalcoholic steatohepatitis. ATP, adenosine 
triphosphate; MMPT, mitochondrial membrane permeability transition; UCP-2, uncoupling 
protein 2; TNF-a, tumor necrosis factor-a. Adopted from Day, 2002. 
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Glucagon and Its Involvement in Regulation of Glucose Homeostasis. 
Glucagon is a 29-amino acid peptide hormone that is produced and secreted by the a-
cells of the islets of Langerhans in the pancreas (Drucker, 1990). In addition to the pancreas, 
the glucagon gene expression also is observed in the small and large intestine, stomach, and 
brain. However, instead of producing glucagon these other tissues produce different bioactive 
peptides. The proglucagon cDNAs isolated from all these tissues are identical, which 
indicates that the glucagon gene produces a single and unique mRNA transcript, despite 
tissue specific glucagon gene localization. 
Translation of glucagon mRNA results in a 180-amino acid peptide called 
preproglucagon, which contains 20-amino acid signal peptide. After elimination of the signal 
peptide, the ' 160-amino acid preglucagon peptide undergoes endoproteolytic processing in a-
cells of the pancreas (Figure 3) and intestinal L-cells (Figure 4), which leads to the 
production of tissue specific bioactive peptides. Prohormone convertases 1 and 2 (PCl and 
PC2) are responsible for tissue-specific posttranslational processing of the preglucagon 
molecule (Tucker et al., 1996). The prohormone convertase 1 is localized in intestinal L-
cells, and PC2 is localized in pancreatic a-cells. Posttranslational processing of preglucagon 
molecule in pancreatic a-cells by PC2 leads to the production of glucagon, a 29-amino acid 
peptide. However, preglucagon processing in intestinal L-cells leads to the production of 
glicentin, oxyntomodulin, glucagon-like peptide 1 (GLP-1), and small amounts of glucagon-
like peptide 2 (GLP-2) and intervening peptide 2 (IP-2). 
Presence of the glucagon sequence in glicentin and oxyntomodulin makes these 
peptides reactive with antisera against glucagon (Holst, 1997), which sometimes makes 































































































































































































































































































































































































































































































































































































































Pancreatic glucagon and intestinal GLP-1 have attracted the most attention because of 
their biological activities. Glucagon-like peptide 1 can stimulate insulin secretion even in 
patients with severe type-2 diabetes mellitus and can inhibit glucagon secretion (Drucker et 
al., 2000; Holst, 1997). In addition, GLP-1 may increase glucose uptake and insulin 
sensitivity. The unique feature of GLP-1 is its very short half-life, which makes difficult to 
study or to use that peptide for therapeutic purposes. 
Glucagon is secreted from the pancreas in a pulsatile fashion, and such a delivery of 
glucagon is more effective in stimulating hepatic glucose output in vivo (Jiang and Zhang, 
2003). Glucagon signals via its receptor, which is localized to the liver, adipose, kidney, 
heart, spleen, pancreatic islets, ovary, and thymus (Unson, 2002). At least two classes of G-
protein coupled receptors, namely Gha and Gq, are involved in signal transduction pathways 
associated with glucagon signalling (Jiang and Zhang, 2003). The activation of the Gha class 
of glucagon receptors leads to the activation of adenylate cyclase (Figure 5), increase in 
intracellular cAMP concentration, and activation of protein kinase A (PKA). Glucagon 
signalling through this pathway is involved in the regulation of hepatic glucose output by 
activating PKA, which results in a stimulation of glycogenolysis and gluconeogenesis and 
inhibition of glycogenesis and glycolysis. The activation of Gq class of glucagon receptors 
leads to the activation of phospholipase C, production of inositol 1,4,5-triphosphate, and 
subsequent release of intracellular calcium. Diacylglycerol, the product of 
phosphatidylinositol 4,5-bisphosphate hydtrolysis by phospholipase C, binds in concert with 
calcium ions to protein kinase C and thereby activates PKA. Activated protein kinase C and 
increased intracellular calcium concentration can have an effect on different metabolic 






















































































































































































































































Regulation of hepatic gluconeogenesis is achieved by the combined action of 
glucagon and insulin. Glucagon activates hepatic gluconeogenesis. It binds to a glucagon 
receptor and stimulates production of the cyclic AMP ( cAMP), a cell second messenger 
molecule. Cyclic AMP activates PKA, which phosphorylates cAMP response element 
binding (CREB) protein (Figure 6). Phosphorylated CREB protein activates peroxisome 
proliferative activated receptor-y co-activator 1 (PGC-1) gene expression (Herzig et al., 
2001). Recently, it was discovered that PGC-1, found before in skeletal muscle and brown 
fat, is also involved in the regulation of hepatic gluconeogenesis (Yoon et al., 2001). 
Peroxisome proliferative activated receptor-y co-activator 1 binds to hepatic nuclear factor-4a 
(HNF-4a) and forkhead transcription factor (FOXOl). This binding of PGC-1 can co-activate 
the expression of gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase 
(PEPCK) and glucose-6-phosphatase (Figure 6). 
Interaction between transcription factor FOXOl and co-activator PGC-1 is required 
for robust activation of gluconeogenesis (Puigserver et al., 2003). Insulin suppresses hepatic 
gluconeogenesis by disrupting the interaction of FOXO 1 and PGC-1. This suppression is 
achieved by insulin-stimulated phosphorylation of FOXOI through protein kinase B (PKB) 
and Akt protein kinase (Akt) pathway (Figure 6). FOXOl phosphorylation does not only 
disrupt the interaction of FOXO 1 and PGC-1, but also excludes FOXO 1 from the nucleus 
(Puigserver et al., 2003). 
Glucagon is not only involved in the regulation of hepatic gluconeogenesis, but it also 
activates fatty acid oxidation by up-regulating gene expression of liver carnitine 
palmitoyltransferase 1 (L-CPT 1) enzyme (Louet et al., 2002). Liver camitine 






















































































































































































































































































































transcription factor to become active (Figure 6). Binding of PGC-1 co-activator to HNF-4a 
transcription factor can strongly up-regulate L-CPT I gene expression. So, glucagon can 
regulate L-CPT I gene expression through abundance of PGC-1 co-activator in the nucleus 
(Louet et al., 2002). Adequate regulation of fatty acid oxidation is required for the prevention 
of fatty liver development in dairy cows, because L-CPT I enzyme activity is lower in cows 
with fatty liver (Mizutani et al., 1999). 
Gluconeogenesis and fatty acid oxidation can also be regulated by nutritional means. 
For example, HNF-4a transcription factor is involved in the regulation of both 
gluconeogenesis and fatty acid oxidation (Hertz et al., 1998; Louet et al., 2002). Fatty acids 
in the form of CoA thioesters can modulate the transcriptional activity of HNF-4a gene and 
affinity of HNF-4a transcription factor for enhancers and/or promoter region on target genes 
(Figure 6). Agonistic ligands of HNF-4a include fatty acyl-CoAs of C14:0 and C16:0 fatty 
acids, whereas antagonistic ligands include w-3, w-6, and C18:0 fatty acyl-CoAs (Hertz et 
al., 1998). 
Gluconeogenesis. 
Control of glucose metabolism postpartum is one of the major metabolic challenges 
with which a dairy cow must cope. At the beginning of lactation, dairy cows have a great 
demand for glucose, which is used primarily for lactose production in milk synthesis 
(Overton et al., 1998). 
The formation of glucose from nonhexose precursors is called gluconeogenesis. 
Gluconeogenesis occurs primarily in liver and to a lesser extend in the kidney. The main 
precursors for gluconeogenesis in dairy cows are propionate, some amino acids (mainly 
16 
alanine and glutamate), lactate, and glycerol (Greenfield et al., 2000a). The importance of 
gluconeogenesis for dairy cows can be explained by the fact that only small amounts of 
carbohydrates can escape microbial fermentation in the rumen and subsequently be available 
for hydrolysis to glucose in the small intestine. The vast majority of the glucose used by a 
dairy cow is endogenously produced via gluconeogenesis. 
Propionate is converted first to succinyl-CoA in a series of reactions in which 
propionyl-CoA carboxylase catalyzes the rate-limiting step (Figure 7). Glutamate is 
converted to a-ketoglutarate. Then, both succinyl-CoA and a-ketoglutarate is converted to 
oxaloacetate via TCA cycle. Oxaloacetate is exported from the mitochondrion into the 
cytosol, where it is used for phosphoenolpyruvate production by PEPCK. Two molecules of 
phosphoenolpyruvate are converted to one molecule of glucose via gluconeogenesis, and 
glucose is released into a blood stream from the liver. 
Alanine and lactate have to be converted to pyruvate before they can enter 
gluconeogenesis (Figure 7). Pyruvate is then converted to oxaloacetate by pyruvate 
carboxylase, which after conversion to phosphoenolpyruvate can undergo reverse glycolysis. 
Glycerol undergoes changes to fructose 1,6-bisphosphate, which enters gluconeogenesis 
(Figure 7). The rate-limiting step for the conversion of glycerol to glucose is a reaction 
catalyzed by fructose 1,6-bisphosphatase. 
In ruminants, PEPCK and glucose-6-phosphatase are the principal enzymes 
responsible for the regulation of glucose production. The explanation for this phenomenon is 
illustrated by the fact that the majority of the glucose in ruminants is produced from 
propionate. Consequently, PEPCK is a good regulatory point. The appropriateness of using 
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Figure 7. Glucose biosynthesis from different gluconeogenic precursors in ruminant animals. 
TCA cycle, tricarboxylic acid cycle. 
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enzyme can catalyze the conversion of glucose-6-phosphate, produced by glycogen 
degradation, to glucose independent of gluconeogenesis. 
Amino acids such as alanine and glutamate are considered to be important 
gluconeogenic precursors in addition to propionate during the first two or three weeks of 
lactation. However, it is very important not to overestimate the significance of amino acids as 
gluconeogenic precursors at the beginning of lactation. The concentration of ammonia and 
glutamine, and blood ammonia to urea ratio increases right after parturition (Zhu et al., 
2000). This indicates dysfunction of ureagenesis, which is accentuated by liver TAG 
accumulation right after calving. Furthermore, amino acids have to be deaminated before 
they can enter gluconeogenesis. The extra ammonia released as a result of amino acid 
deamination leads to an increased blood ammonia concentration and possible overloading of 
the urea cycle. 
The feeding of extra rumen-undegradable protein (RUP) to ruminant animals before 
and after parturition has been proposed to create a pool of extra amino acids that could be 
used for glucose biosynthesis. However, feeding high amounts of crude protein (CP) and 
RUP (CP=16 and 18%, RUP=33 and 40% on dry matter basis) to dairy cows during 28 days 
before parturition resulted in decreased feed intake and milk production postpartum 
(Greenfield et al., 2000b ). This result can be explained by the fact that excess of protein in a 
diet could overwhelm the ability of liver to detoxify ammonia to urea at calving and right 
after it. Consequently, the current NRC guidelines for protein content in diets of dry cows 
(12% CP and 26% RUP on dry matter basis) seems adequate (Greenfield et al., 2000b). 
Feeding extra RUP to dairy cows with fatty liver postpartum led to further TAG 
accumulation by the liver and did not have an effect on gluconeogenesis (Murondoti et al., 
19 
2002). In summary, even though alanine and glutamate are good substrates for glucose 
biosynthesis, it is not reasonable to focus on them as a potential solution to the problem of 
glucose production during the first weeks of lactation. 
During lactation, hepatic gluconeogenesis is the major source of glucose production 
in ruminants (Young, 1977). Therefore, there was an attempt to evaluate the effects of 
overfeeding during a dry period together with fatty liver development on the function of key 
gluconeogenic enzymes around parturition (Rukkwamsuk et al., 1999a). The activity of 
PEPCK in the liver of cows overfed during a dry period was significantly lower than that in 
the liver of control cows. The possible explanation underlying this finding is that overfed 
cows were able to get most of their glucose from the ration, and, because of that, the rates of 
their hepatic gluconeogenesis were low. The activity of PEPCK continued to be low after 
parturition in the liver of overfed cows because of low adaptability of their livers to 
gluconeogenesis during the dry period. Overfed cows had higher rates of lipolysis and, 
consequently, higher glycerol concentration in blood. However, the increase in blood 
glycerol concentration did not change the activity of liver fructose 1,6-bisphosphatase in 
overfed cows. Possibly, blood glycerol concentration was not high enough to cause an 
increase in the function of the enzyme. Surprisingly, the activity of glucose-6-phosphatase 
was higher postpartum in the liver of overfed cows. Those cows possibly had higher rates of 
glycogen degradation than did control cows because of limited availability of glucose from 
gluconeogenesis in overfed cows. 
The decreased rates of hepatic gluconeogenesis in fatty liver cows could be explained 
not only by feeding high energy diet during dry period (Rukkwamsuk et al., 1999a), but also 
by a fat infiltration of liver tissue itself (Cadomiga-Valino et al., 1997). Interestingly, 
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glucagon was able to increase the rates of hepatic gluconeogenesis regardless of whether 
liver tissue had high TAG concentration or not (Cadomiga-Valino et al., 1997). 
Preventatives and Treatments of Fatty Liver Disease. 
Fatty liver, ketosis, and other peripaturient diseases associated with them decrease 
productivity, reproductive performance, and well being of dairy cows. These all together 
contribute to economic losses of dairy producers. Development of a preventive and/or 
treatment for pathological fatty liver would place a tool in the hands of veterinarians and 
dairy farmers that would improve the productivity, health, and well being of many cows thus 
resulting in major savings for dairy producers. 
Many research groups are trying to use different strategies to prevent or treat fatty 
liver disease. There was an attempt to decrease blood NEFA and liver TAG concentrations 
without decreasing blood glucose concentration and feed intake in healthy dairy cows during 
the first week of lactation by a single intramuscular injection of several doses of slow-release 
insulin (Hayirli et al., 2002). The results of this study showed that, even though there was 
some decrease in blood NEF A and liver TAG concentrations and increase in dry matter 
intake and milk production after insulin administration, high blood insulin concentration was 
not able to suppress lipolysis from adipose tissue sufficiently because of existence of some 
degree of insulin resistance in dairy cows right after calving. 
Another attempt to decrease blood NEFA concentration and prevent liver TAG 
accumulation in dairy cows postpartum was done by using a 3-day drenching with 500 ml of 
propylene glycol, 454 g of fat, or the combination of both beginning at day 0 postpartum 
(Pickett et al., 2003). Even though drenching with propylene glycol decreased blood NEFA 
21 
concentration in dairy cows during the first 21 days postpartum, it did not have any effects on 
liver TAG concentration. The possible explanation to the inability of propylene glycol to 
decrease liver TAG concentration lies in the magnitude of a difference in blood NEFA 
concentration between control and the treatment group. The difference was not big enough to 
cause any changes in liver TAG concentration. 
Dairy cows have a low capacity for synthesis and secretion of VLDL from liver, 
which is considered to be a contributing factor for the development of fatty liver disease 
(Grummer, 1993). Increasing VLDL synthesis and secretion could prevent and/or treat fatty 
liver. There was an attempt to feed extra rumen-protected choline (RPC) during 
periparturient period to increase phosphatidylcholine synthesis and VLDL production and 
secretion in dairy cows (Piepenbrink and Overton, 2003). There were no changes in plasma 
BHBA, NEFA and liver TAG concentrations after feeding extra RPC. However, the hepatic 
capacity for storage of palmitate in the form of TAG within liver slices tended to decrease as 
the amount of RPC consumed by cows increased. The hepatic fatty acid oxidation to C02 
was not affected by dietary choline. 
The idea of using glucagon for fatty liver treatment and/or prevention originated from 
investigators who studied secretion and clearance rates of glucagon in dairy cows under 
different physiological conditions and changes in metabolite and hormone concentrations in 
response to glucagon administration (De Boer et al., 1986). A single intravenous glucagon 
injection increased blood insulin and glucose concentrations, thus creating a condition that 
could lead to inhibition of lipolysis from adipose. Then, metabolic responses to 14-d 
intravenous infusions of glucagon in lactating dairy cows were studied (She et al., 1999a). 
The continuous glucagon infusion increased plasma glucose and insulin concentrations and 
22 
did not change the concentrations of plasma NEFA, BHBA, and urea. Liver glycogen 
concentration was not significantly affected by glucagon but increased dramatically after the 
cessation of glucagon administration. The continuous intravenous glucagon administration 
decreased PEPCK mRNA concentration in normal cows but did not have any effects on 
PEPCK mRNA in cows with fatty liver (She et al., 1999b). However, the concentration of 
PEPCK was higher in fatty liver cows. There was a decrease in PEPCK mRNA in normal 
midlactation cows after glucagon infusion. The data indicate that the expression of PEPCK 
gene in normal cows is decreased after glucagon administration because of inhibitory effect 
of insulin, which is secreted to balance elevated carbohydrate status after glucagon infusion. 
The inability of glucagon to decrease PEPCK mRNA in fatty liver cows may be related to 
some degree of insulin resistance existing in those cows. 
Intravenous infusions of glucagon for 14 d alleviated fatty liver and ketosis in 
lactating dairy cows (Hippen et al., 1999a). Feeding extra com during the dry period combine 
with feed restriction and diet supplementation with ketogenic precursor postpartum were 
used to induce fatty liver in those cows. In this study, glucagon did not increase plasma 
insulin concentration but decreased plasma BHBA and NEFA and liver TAG concentrations, 
and increased plasma glucose concentration. Liver glycogen concentration was not affected 
by glucagon but increased after the end of glucagon administration. 
To make a glucagon therapy easily applicable to field conditions in the dairy industry, 
subcutaneous glucagon injections were used to test the treatment of fatty liver in transition 
dairy cows (Bobe et al., 2003b). Glucagon was able to increase plasma glucose and insulin 
concentrations and decrease plasma NEF A concentration. However, the treatment effect of 
glucagon, as based on the changes in liver TAG concentration, was observed only in older 
23 
cows. Subcutaneous glucagon injections did not have any effects on the concentration of 
different fractions of lipoproteins in plasma (Bobe et al., 2003a). 
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PREVENTION OF FATTY LIVER IN TRANSITION DAIRY 
COWS BY 14-DAY SUBCUTANEOUS GLUCAGON 
INJECTIONS 
A paper to be submitted to the Journal of Dairy Science 
Rafael A. Nafikov, Burim N. Ametaj, Kenneth J. Koehler, J. W. Young, 
and Donald C. Beitz 
Abstract 
The main objective of this study was to test the extent to which subcutaneous 
glucagon injections for 14 days beginning at d 2 postpartum would prevent fatty liver 
development in transition dairy cows. Twenty-four multiparous Holstein cows were fed 6 kg 
of cracked com in addition to dry cow ration during last 30 d of a dry period to induce fatty 
liver development postpartum. Subcutaneous glucagon injections at either 7 .5 or 15 mg/d 
dosages or saline as a control were given 3 times per day for 14 d beginning at d 2 
postpartum. Glucagon administration at a dosage of 15 mg/d prevented liver triacylglycerol 
accumulation and, consequently, fatty liver development in transition dairy cows postpartum. 
Glucagon administration at 7.5 mg/d dosage showed a potential for fatty liver prevention. 
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Glucagon administration increased plasma glucose and insulin concentrations and decreased 
plasma nonesterified fatty acid concentration. There were no significant effects of glucagon 
administration on plasma B-hydroxybutyrate (BHBA) concentration. Cows treated with the 
15 mg/d dosage of glucagon, however, tended to show an increase in plasma BHBA 
concentration around d 9 postpartum. Glucagon had no effects on feed intake and milk 
production of dairy cows. Moreover, milk composition was not altered by subcutaneous 
glucagon injections. Milk urea concentration decreased, and plasma urea concentration 
tended to decrease during glucagon administration, which indicates that treatment with 
glucagon may improve protein utilization. Liver glycogen concentration was not affected by 
glucagon administration. There were no significant differences in body condition scores 
between cows from different treatment groups throughout the study. Our results show that 
subcutaneous glucagon injections can be used for fatty liver prevention in transition dairy 
cows. 
Introduction 
Transition dairy cows defined as 3 wk prior to and 3 wk after parturition, are at high 
risk for the development of different metabolic diseases (Drackley, 1999). Fatty liver is one 
of them. The prevalence of fatty liver in dairy herds could reach up to 50% (Jorritsma et al., 
2000a). The consequences of fatty liver development are decreased reproductive success and 
suppressed immune function (Jorritsma et al., 2000b; Wentink et al., 1999). Increased liver 
triacylglycerol (TAG) concentration increases the interval from parturition to first ovulation 
and decreases functional capacities of polymorphonuclear neutrophilic granulocytes derived 
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from blood and uterus (Rukkwamsuk et al., 1999b; Zerbe et al., 2000). Fatty liver does not 
develop alone and could be associated with other periparturient diseases such as ketosis, 
retained fetal membranes, endometritis, displaced abomasum, mastitis, and milk fever 
(Katoh, 2002; Van Winden et al., 2003). Ketosis is believed to be associated with fatty liver, 
which is commonly the prerequisite for the development of ketosis (Katoh, 2002). Being able 
to prevent and/or treat ketosis and other metabolic diseases is very important, because they 
cause substantial economical losses to dairy farmers (Fourichon et al., 1999). 
Around parturition dairy cows are in a state of negative energy balance (NEB), 
because they cannot meet their nutrient requirements for maintenance, fetus growth and milk 
production from feed consumption (Jorritsma et al., 2003). At the onset of lactation, the 
mammary gland has increased demands for glucose, used primarily for lactose biosynthesis, 
which exacerbates NEB, because glucose is in short supply. To meet energy requirements, 
cows mobilize fatty acids from adipose tissue, which results in an elevated blood 
nonesterified fatty acid (NEFA) concentration (Drackley, 1999; Grummer, 1993). Excess 
blood NEFA is taken up by the liver and metabolized in different ways. Nonesterified fatty 
acids can be oxidized completely to carbon dioxide or incompletely to ketone bodies, 
esterified into TAG for storage in the liver, or secreted into blood as a part of very low 
density lipoproteins (VLDL). When the rates of NEFA esterification into TAG for storage 
exceed the rates of NEFA disposal, fatty liver can develop. The exact causes of fatty liver are 
unknown. However, any factor that causes increased lipid mobilization could be responsible 
for disease development. Periparturient ketosis is associated with fatty liver and developed 
because of the condition of increased liver lipid infiltration and decreased liver glycogen 
(Drackley et al., 1992). 
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Hepatic gluconeogenesis is impaired in cows fed high concentrate diets during the dry 
period because of low phosphoenol-pyruvate carboxykinase (PEPCK) activity 1 wk before 
and 2 wk after parturition (Rukkwamsuk et al., 1999a). As a result, inadequate glucose 
production further increases the ongoing high rates of lipolysis and promotes fatty liver 
development. The fatty liver condition itself, however, can inhibit ureagenesis, leading to 
increased blood ammonia concentration (Zhu et al., 2000), which can decrease the rates of 
hepatic gluconeogenesis from propionate (Overton et al., 1999). Thus, it was demonstrated in 
vitro that hepatic TAG accumulation can decrease the rates of gluconeogenesis (Cadomiga-
Valino et al., 1997). 
Glucagon is a 29-amino acid peptide hormone produced and secreted by the a-cells in 
the islets of Langerhans in the pancreas. The secretion of glucagon occurs in a pulsatile 
fashion, which generates a maximal effect on hepatic glucose output. Glucagon is involved in 
the regulation of glucose homeostasis by stimulating gluconeogenesis and glycogenolysis 
and by inhibiting glycogenesis and glycolysis. Half-life of a glucagon molecule in blood of 
dairy cows is about 5 min. (De Boer et al., 1986). Based on in vitro studies glucagon has 
been considered for a long time to have a lipolytic effect in humans (Richter et al., 1989). 
However, recent data indicate that glucagon does not have a direct effect on the rates of 
lipolysis in human adipose tissue (Bertin et al., 2001). In rats, the glucagon to insulin molar 
ratio is responsible for the control of ketogenesis, but it has no effect on the rates of lipolysis 
(Ubukata et al., 1996). Thus, a high glucagon to insulin ratio increases the concentration of 
ketone bodies in blood and a low glucagon to insulin ratio has an opposite effect. 
Previously, we demonstrated that 14-d intravenous infusion of glucagon could be 
used to treat fatty liver and, associated with it, ketosis in early lactation cows (Hippen et al., 
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1999a). In this study, feeding extra com grain to dry cows together with energy restriction 
and diet supplementation with 1,3-butanediol postpartum were used to induce fatty liver and 
ketosis in dairy cows. Intravenous infusions of glucagon, however, are not practical for use in 
the dairy industry, and the conditions associated with naturally occurring fatty liver and 
ketosis could be different from those artificially created in the Hippen et al. study. The 
objectives of this study were to determine whether subcutaneous glucagon injections for 14 d 
beginning at d 2 postpartum would prevent development of fatty liver in transition dairy 
cows and to evaluate the effects of glucagon treatment on feed intake, milk production, and 
blood composition of dairy cows. 
Materials and Methods 
Experimental Design 
In this study, 24 multiparous Holstein cows were randomly assigned to saline 
(control), 7.5 mg/d, or 15 mg/d glucagon treatment groups with 8 cows per group. One cow 
from the 7.5 mg/d of glucagon treatment group was dropped from the study, because she 
developed a fatty liver disease prepartum before we started the treatment administration for 
preventive purposes. During wk 4 of gestation, all cows were supplemented with 6 kg of 
cracked com in addition to their regular dry cow diet (Bobe et al., 2003b), which was fed 
according to NRC requirements (National Research Council, 2001), to stimulate the 
development of fatty liver disease postpartum (Hippen et al., 1999a). Cows were housed in a 
straw-bedded free-stall with free access to water and hay. After parturition, cows were 
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housed in a tie-stall barn and fed ad libitum a lactation diet (Bobe et al., 2003b) that was 
formulated to meet NRC requirements (National Research Council, 2001). 
Beginning at d 2 postpartum, cows were injected subcutaneously with saline (0.15 M 
NaCl), 7.5 mg/d, or 15 mg/d of glucagon for 14 d. Injections were given in the area between 
the fifth and seventh intercostal space three times per day in 8-h intervals. The volume of a 
single injection was 60 ml. Lyophilized glucagon (donated by Eli Lilly and Co., 
Indianapolis, IN) was dissolved in 0.15 M NaCl (pH 10.25) at 41.67 mg/Land 83.33 mg/L to 
create the dosage of 7.5 and 15 mg/d of glucagon, respectively. Glucagon solution were 
prepared every other day, stored at 4 °c and used within 48 h when needed. To prevent 
adherence of glucagon, all glassware and utensils were rinsed with 1 % bovine serum albumin 
in 0.15 M NaCl before use. All animals were treated in accordance with guidelines 
established by the Iowa State University Committee on Animal Care. 
Sampling and Analysis 
Liver. Liver samples were obtained by puncture biopsies at d -4, 2, 6, 9, 16, 20, 27, 
34, and 42 postpartum and stored at -80 c0 for later analysis for concentration of total lipids, 
TAG, phospholipids, total cholesterol, and glycogen. Total lipid concentration of liver was 
determined gravimetrically by using the Folch method (Folch et al., 1957) with the following 
modifications. Liver tissue with wet weight between 300-400 mg was homogenized in 8 ml 
of chloroform-methanol (2:1 vol/vol) in a screw-top 25 x 150 extraction tube and sonicated 
for 30 s (model 350 sonifier, Bronson Sonic Power Corp., Danbury, CT). The samples were 
shaken for 1 h (model 75 wrist-action shaker, Burrel Scientific, Pittsburg, PA), and 2 ml of 
0.15 M NaCl was added. After vortexing for a few seconds, the mixture was centrifuged at 
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500 x g for 20 min. (model K centrifuge, International Equipment Co., Needham Heights, 
MA), and the methanol-water layer was aspirated. 
The chloroform-containing fraction was filtered through a Buchner funnel and a 42.5 
mm glass microfiber filter (Whatman International Ltd., Maidstone, England) and washed 
three times with 2, 4, and 4 ml of chloroform, respectively. Liver total lipid extract was dried 
under constant air flow at 50 c0 for 2.5 h (SC/48R sampler concentrator, Brinkmann 
Instruments, Inc., Westbury, NY). Liver total lipid extraction was performed twice using the 
same set of liver samples. One of the liver total lipid extracts was used for liver phospholipid 
and total cholesterol analysis, and the other extract was used for total lipid and TAG 
determination. For phospholipid and total cholesterol determination, dried liver lipid extracts 
were reconstituted with 5 ml of 1 % Triton X-405 (Amresco Inc., Solon, OH) in 0.15 M NaCl 
at 37 c0, and liver phospholipid (Phospholipids B kits number 991-38492, Wako, Richmond, 
VA) and total cholesterol (Cholesterol kit number C7510, Pointe Scientific, Lincoln Park, 
Ml) concentrations were determined on a microplate spectrophotometer (SPECTRA max 
Plus, Sunnyvale, CA). For liver TAG determination, dried liver lipids were reconstituted 
with chloroform, and a small aliquot of the liver lipid in chloroform solution was used for 
analysis. After chloroform evaporation, lipids were subjected to base hydrolysis in a solution 
containing 20% of 2 N KOH and 80% of 96% ethanol for 1hat80 c0. 
The pH of the mixture was neutralized by 12.1 N hydrochloric acid, and the 
concentration of a glycerol in the mixture was determined enzymatically (TAG kit number 
T7532, Pointe Scientific, Lincoln Park, Ml) and expressed as a TAG concentration. Liver 
glycogen determination was done as described earlier (Bobe et al., 2003b ). 
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Plasma. Blood samples were collected in the morning from the coccygeal vein at d 1 
through 17, 20, 27, 34, and 41 postpartum. During the treatment period, blood samples were 
taken at 1 h after the morning injection of glucagon or saline. We used 10-ml Vacutainer 
tubes (Beckton Dickinson and Co., Rutherford, NJ) containing Na3-EDTA for blood 
sampling. After centrifugation, blood plasma samples were stored at -20 c0 until further 
analysis for the concentration of glucose (glucose kit number 315 Sigma), NEPA (NEFA-C 
kit number 994-75409; Wako, Richmond, VA), BHBA (BHBA; Pointe Scientific, Lincoln 
Park, MI), PUN (BUN kit number B 7552, Pointe Scientific; Lincoln Park, Ml), and 
glucagon (glucagon kit number GL-32K; LINCO Research, Inc. St Charles, MO). Aprotinin 
(Boehringer -Mannheim, Indianapolis, IN), a protease inhibitor, was added at 500 KIU to the 
1 ml plasma to be analyzed for glucagon. 
Plasma insulin concentration was determined by RIA using antisera for bovine insulin 
(Bovine Insulin Antisera catalog number 1010, LINCO Research, Inc.; St. Charles, MO). The 
rest of the reagents for RIA were from the rat insulin kit (rat insulin RIA kit number RI-13K). 
Bovine insulin (bovine insulin catalog number I 0516; Sigma) standards were prepared in the 
prescribed assay buffer. 
Other measurements. Feed intake was measured twice daily at d 1 through 17 
postpartum. Cows were milked at 6.30 and 18.30 h, and production was recorded daily at d 1 
through 41 postpartum. Milk samples were collected from two adjacent milking at d 2, 6, 9, 
16, 20, 27, 34, and 41 postpartum and analyzed for fat, protein, lactose, and urea N by mid-
infrared spectrophotometry (Milk-0-Scan 203, Foss Food Technology, Eden Prairie, MN). 
Body condition scores (BCS) were evaluated by three individuals at d -22, -9, 5, 19, and 32 
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postpartum. Cows were tested for urinary ketones (i.e., acetone plus acetoacetate, Ketostix®; 
Miles Inc. Diagnostics Division, Elkhart, IN). 
Statistical Analysis 
Data were analyzed as repeated measures using the MIXED procedure of SAS, 
Version 8.2 (2001). Effects of 7.5 and 15 mg/d of glucagon administration on response 
variables were evaluated by comparing each glucagon-treated group with the saline (control) 
group. Separate comparisons were made for data obtained during the treatment period and 
the post treatment period. 
The statistical models contained response variables as the dependent variables. The 
fixed effects were treatment (saline, 7.5, and 15 mg/d of glucagon), time, and treatment by 
time interaction. A different set of random effects was used for the set of measurements taken 
on each cow. The Toeplitz covariance structure was selected based the Schwarz's Bayesian 
Information Criterion (BIC, smaller is better), the design of the study, and the biology of the 
experiment. The Toeplitz covariance structure assumes equal variances on the main-diagonal, 
equal correlations for any pair of measurements equally distant in time, but different 
correlation for pairs of observations with separation in time. The logarithmic transformation 
of some data was used to meet the requirements for normality. The overall effects of the 
different treatment administration were evaluated by comparing changes in response 
variables from the glucagon-treated groups with corresponding changes in response variables 
from saline (control) group by using a t-test in the LSMEAN statement. The 
KENW ARDROGER option was used to obtain the correct degrees of freedom. Means and 
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SEM shown in the figures were calculated from the original, non-transformed data. 
Significance was declared at P:S0.05. 
Results 
Liver lipid composition and glycogen. Glucagon administration tended to prevent 
lipid accumulation by liver of lactating dairy cows (Figure lA), although the effects of 7.5 
and 15 mg/d of glucagon treatments were not significant (P:S0.096 and P:S0.057, 
respectively). A postpartal increase in liver TAG concentration was prevented by glucagon 
administration at 15 mg/d dosage (P:S0.028), (Figure lB). Liver TAG concentration in cows 
from 7 .5 mg/d of glucagon treatment group, however, was not as effectively suppressed 
(P:S0.20). Concentrations of liver phospholipids and total cholesterol (Figure 1 C and 1 D, 
respectively) in the glucagon-treated groups were not significantly different from those 
concentrations in the control group (liver phospholipids: P:S0.12 and P:S0.31 for 7.5 and 15 
mg/d of glucagon treatment groups, respectively; liver total cholesterol: P:S0.41 and P:S0.32 
for 7.5 and 15 mg/d of glucagon treatment groups, respectively). Nevertheless, the 
concentrations of liver phospholipids and total cholesterol tended to be higher in the control 
group than in the glucagon-treated groups. There were significant time effects on liver TAG, 
phospholipids, and total cholesterol concentrations (P:S0.024, P:S0.038, and P:S0.024, 
respectively) for the posttreatment period (d 17 through 41 postpartum). 
Liver glycogen concentration declined after parturition through d 6 postpartum in all 
treatment groups (Figure 2). Then, it started to rise with different paces for the different 
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Figure 1. Liver lipid composition of cows treated with saline, 7.5, and 15 mg/d of glucagon. 
A. Liver total lipids. Effects of 7.5 and 15 mg/d of glucagon administration during treatment 
period are PS0.096 and PS0.057, respectively; and during post treatment period are PS0.21 
and PS0.23, respectively. SEM= 0.36 to 0.78. B. Liver TAG. Effects of 7.5 and 15 mg/d of 
glucagon administration during treatment period are PS0.20 and PS0.028, respectively; and 
during post treatment period are PS0.52 and PS0.24, respectively. Time effect for post 
treatment period is PS0.024. SEM= 0.38 to 0.84. C. Liver phospholipids. Effects of 7.5 and 
15 mg/d of glucagon administration during treatment period are PS0.12 and PS0.31, 
respectively; and during post treatment period are PS0.73 and PS0.87, respectively. Time 
effect for post treatment period is PS0.038. SEM= 0.07 to 0.11. D. Liver total cholesterol. 
Effects of 7.5 and 15 mg/d of glucagon administration during treatment period are PS0.41 
and PS0.13, respectively; and during post treatment period are PS0.91 and PS0.32, 
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Figure 2. Liver glycogen concentration of cows treated with saline, 7.5, and 15 mg/d of 
glucagon. Effects of 7.5 and 15 mg/d of glucagon administration during treatment period are 
P::;0.11 and P::;0.36, respectively; and during post treatment period are P::;0.094 and P::;0.045, 
respectively. Time effect for treatment period is P<0.0001. Treatment by time interaction for 
post treatment period is P::;0.0025. SEM= 0.17 to 0.20. 
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significant effects of glucagon administration on liver glycogen concentration during the 
treatment period (PS0.11 and PS0.36 for 7.5 and 15 mg/d of glucagon treatment groups, 
respectively). However, glucagon administration at 15 mg/d dosage caused an increase in 
liver glycogen concentration during the posttreatment period (PS0.045). Liver glycogen 
concentration also tended to be higher in the 7.5 mg/d of glucagon treatment group during the 
posttreatment period as compared with that of the control (PS0.094). There were a significant 
time effect on liver glycogen concentration for treatment period (P<0.0001) and a significant 
time by treatment interaction for posttreatment period (PS0.0025). 
Plasma metabolites. Plasma glucose concentration increased during the treatment 
period in 7.5 and 15 mg/d of glucagon treatment groups (P<0.0001 and P<0.0001, 
respectively) in a dosage-dependent manner (PS0.017, Figure 3A). There were no significant 
differences in plasma glucose concentrations after the end of treatment period. Plasma NEF A 
concentration was very high in cows from all treatment groups around d 2 postpartum 
(Figure 3B). After glucagon administration, plasma NEFA concentration declined rapidly as 
compared with that of the control group. As a result, plasma NEF A concentration was lower 
in glucagon-treated groups (PS0.046 and PS0.007 for 7.5 and 15 mg/d of glucagon treatment 
groups, respectively) during the treatment period. There were significant time effects on 
plasma NEFA concentration for treatment (PS0.0089) and posttreatment (PS0.0013) periods. 
Plasma BHBA concentration tended to be lower in the 7 .5 mg/d of glucagon treatment group 
(P:s;0.35, Figure 3C) during treatment period. Glucagon administration at 15 mg/d dosage did 
not have a significant effect on plasma BHBA concentration (P:s;0.77). Moreover, the pattern 
of changes in BHBA concentration during the treatment period was the same for both 
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Figure 3. Plasma metabolite concentrations of cows treated with saline, 7.5, and 15 mg/d of 
glucagon. A. Plasma glucose. Effects of 7.5 and 15 mg/d of glucagon administration during 
treatment period are P<0.0001 and P<0.0001, respectively; and during post treatment period 
are P:S0.96 and P:S0.33, respectively. Dosage effect for treatment period is P:S0.017. 
SEM=l.31to1.74. B. Plasma NEFA. Effects of 7.5 and 15 mg/d of glucagon administration 
during treatment period are P:S0.046 and P:S0.007, respectively; and during post treatment 
period are P:S0.99 and P:S0.48, respectively. Time effect for treatment period is P:S0.0089; 
and for post treatment period is P:S0.0013. SEM=26.52 to 64.80. C. Plasma BHBA. Effects 
of 7.5 and 15 mg/d of glucagon administration during treatment period are P:S0.35 and 
P:S0.77, respectively; and during post treatment period are P:S0.69 and P:S0.43, respectively. 
SEM=0.49 to 1.37. D. Plasma urea. Effects of 7.5 and 15 mg/d of glucagon administration 
during treatment period are P:S0.24 and P:S0.17, respectively; and during post treatment 
period are P:S0.65 and P:S0.76, respectively. Time effect for treatment period is P:S0.0008; 
and for post treatment period is P:S0.034. SEM=0.76 to 0.89. 
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15 mg/d of glucagon and saline treatment groups. Plasma urea concentration tended to be 
lower in glucagon-treated groups (P:S0.24 and P:S0.17 for 7.5 and 15 mg/d of glucagon 
treatment groups, respectively, Figure 3D) during the treatment period. There were 
significant time effects on plasma BHBA concentration during the treatment (P:S0.0008) and 
posttreatment (P:S0.034) periods. 
Plasma insulin concentration rose steadily after the beginning of glucagon 
administration (Figure 4A). Cows from the glucagon treatment groups had higher plasma 
insulin concentration as compared with that of the control group (P:S0.012 and P:S0.0011 for 
7.5 and 15 mg/d of glucagon treatment groups, respectively) during the treatment period. 
There were no significant differences in plasma insulin concentration between the glucagon 
treatment groups and the control group during the posttreatment period. 
Milk production and composition. Glucagon administration did not have a 
significant effect on milk production during the treatment (P:S0.78 and P:S0.51 for 7.5 and 15 
mg/d of glucagon treatment groups, respectively) and posttreatment (P:S0.46 and P:S0.50 for 
7.5 and 15 mg/d of glucagon treatment groups, respectively) periods (Figure 5). There were 
significant time effects on milk production during the treatment (P<0.0001) and 
posttreatment (P:S0.049) periods. 
Although milk lactose concentration tended to be slightly higher in 7 .5 mg/d of 
glucagon treatment group it was not a statistically significant difference either during the 
treatment (P:S0.19) or posttreatment (P:S0.11) periods as compared with that of the control 
group (Figure 6A). Glucagon administration at 15 mg/d dosage did not have a significant 
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Figure 4. Plasma hormone concentrations of cows treated with saline, 7.5, and 15 mg/d of 
glucagon. A. Plasma insulin. Effects of 7.5 and 15 mg/d of glucagon administration during 
treatment period are P:S0.012 and P:S0.0011, respectively; and during post treatment period 
are P:S0.33 and P:S0.62, respectively. SEM=0.05 to 0.08. B. Plasma glucagon. Effects of 7.5 
and 15 mg/d of glucagon administration during treatment period are P:S0.47 and P:S0.86, 
respectively; and during post treatment period are P:S0.80 and P:S0.82, respectively. 
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Figure 5. Milk production of cows treated with saline, 7.5, and 15 mg/d of glucagon. Effects 
of 7.5 and 15 mg/d of glucagon administration during treatment period are P:'.S0.78 and 
P:S0.51, respectively; and during post treatment period are P:'.S0.46 and P:'.S0.50, respectively. 
Time effect for treatment period is P<0.0001; and for post treatment period is P:'.S0.049. 
SEM=l.32 to 2.79. 
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Figure 6. Milk composition of cows treated with saline, 7.5, and 15 mg/d of glucagon. A. 
Milk lactose. Effects of 7.5 and 15 mg/d of glucagon administration during treatment period 
are P:S0.19 and P:S0.96, respectively; and during post treatment period are P:S0.11 and 
P:S0.71, respectively. Time effect for treatment period is P<0.0001. SEM=0.078 to 0.083. B. 
Milk fat. Effects of 7.5 and 15 mg/d of glucagon administration during treatment period are 
P:S0.71 and P:S0.66, respectively; and during post treatment period are P:S0.63 and P:S0.83, 
respectively. Time effect for treatment period is P:S0.0031. SEM=0.11 to 0.22. C. Milk 
protein. Effects of 7.5 and 15 mg/d of glucagon administration during treatment period are 
P:S0.13 and P:S0.20, respectively; and during post treatment period are P:S0.64 and P:S0.52, 
respectively. Time effect for treatment period is P<0.0001; and for post treatment period is 
P:S0.028. SEM=0.052 to 0.098. D. Milk urea. Effects of 7.5 and 15 mg/d of glucagon 
administration during treatment period are P:S0.0208 and P:S0.0018, respectively; and during 
post treatment period are P:S0.50 and P:S0.49, respectively. SEM= 0.55 to 1.34. 
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periods, respectively). There was a time effect on milk lactose concentration during the 
treatment period (P<0.0001). Milk fat concentration was not affected by glucagon treatments 
during both the treatment (P:S:0.71 and P:::;0.66 for 7.5 and 15 mg/d of glucagon treatment 
groups, respectively) and posttreatment (P:S:0.63 and P:S:0.83 for 7.5 and 15 mg/d of glucagon 
treatment groups, respectively) periods (Figure 6B). There was a significant time effect on 
milk fat concentration during the treatment period (P:S:0.0031 ). Milk protein concentration 
declined rapidly since the beginning of lactation until it reached a base line in the range 
between 2.50 and 2.75% (Figure 6C). There were no significant differences in milk protein 
concentration between glucagon-treated groups and the control group during the treatment 
(P:S:0.13 and P:S:0.20 for 7.5 and 15 mg/d of glucagon treatment groups, respectively) and 
posttreatment (P:S:0.64 and P:S:0.83 for 7.5 and 15 mg/d of glucagon treatment groups, 
respectively) periods. There were significant time effects on milk protein concentration 
during the treatment (P<0.0001) and posttreatment (P:S:0.028) periods. Milk urea 
concentration was significantly higher in the control group as compared with that of the 
glucagon-treated groups (P:S:0.0208 and P:S:0.0018 for 7.5 and 15 mg/d of glucagon treatment 
groups) during the treatment period (Figure 6D). There were no significant differences in 
milk urea concentration between the glucagon-treated groups and the control group during 
the posttreatment period. 
Feed intake and BCS. Feed intake of dairy cows was not affected by glucagon 
administration during the treatment period (P:S:0.99 and P:S:0.95 for 7.5 and 15 mg/d of 
glucagon treatment groups, respectively, Figure 7). However, cows given 7.5 mg/d glucagon 
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Figure 7. Feed intake of cows treated with saline, 7.5, and 15 mg/d of glucagon. Effects of 
7.5 and 15 mg/d of glucagon administration during treatment period are P:::;0.99 and P:::;0.95, 
respectively. SEM=4.28 to 6.12. 
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between cows from all treatment groups (Figure 8). Precalving BCS were not as high as in 
an earlier study from our research group (Hippen et al., I999a), which slightly decreased the 
severity of fatty liver development in the present study. 
Discussion 
Subcutaneous glucagon injections administered for I 4 d beginning at d 2 postpartum 
tended to prevent liver total lipid accumulation (Figure IA). However, the differences in liver 
total lipids between the glucagon-treated groups and the control group were not statistically 
significant because of the small numbers of cows in the treatment groups and the high 
variability among cows within treatment groups. The peak of lipid accumulation by liver was 
around d 9 postpartum, which agrees with data of others (Greenfield et al., 2000b). 
Glucagon administration at I5 mg/d dosage prevented liver TAG accumulation as 
compared with that of the control group (Figure IB). However, the decrease in liver TAG 
accumulation provided by the 7 .5 mg/d dosage of glucagon was smaller and statistically 
insignificant. 
Liver phospholipid (Figure IC) and total cholesterol (Figure ID) concentrations 
tended to be higher in control cows as compared to glucagon-treated cows. Our data disagree 
with earlier published work (Bobe et al., 2003a). An increase in liver phospholipid and total 
cholesterol concentrations in control cows was caused by liver TAG accumulation. The 
percentages of liver TAG, phospholipid, and total cholesterol nearly added up to the 
percentages of liver total lipids determined gravimetrically, showing indirectly that analysis 
of liver lipid composition included all major lipids. 
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Figure 8. Body condition scores of cows from saline, 7.5, and 15 mg/d of glucagon treatment 
groups. Difference in body condition score between saline and 7.5 mg/d of glucagon 
treatment groups, saline and 15 mg/d of glucagon treatment groups, and 7.5 mg/d and 15 
mg/d of glucagon treatment groups throughout the study are P<0.9971, P<0.9703, and 
P<0.9525, respectively. SEM=0.12 to 0.23. 
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Liver glycogen concentration declined from d 0 until d 6 postpartum in cows from all 
treatment groups and then started to rise, reaching precalving values around d 32 postpartum 
(Figure 2). There were no significant treatment differences in liver glycogen concentrations 
during the treatment period. This suggests that plasma glucose concentration did not increase 
in glucagon-treated groups at the expense of glycogen degradation. Moreover, glucagon had 
an inhibitory effect on glycogen synthesis, because, despite a higher plasma glucose 
concentration in cows from the glucagon-treated groups (Figure 3A), liver glycogen 
concentration was not significantly different between treatments during the treatment period. 
The inhibitory effect of glucagon on glycogen synthesis observed in our study agrees with 
data from the literature (Jiang and Zhang, 2003). After glucagon administration, liver 
glycogen concentration started to rise very steeply, reaching very high levels at d 20 and 27 
postpartum, which were significantly different from the values in the control group. A huge 
increase in liver glycogen concentration after the end of glucagon administration can be 
explained by the fact that there were no significant differences in plasma glucose 
concentration after the end of treatment period and most extra glucose produced via 
gluconeogenesis in glucagon-treated groups after the end of treatment period was used for 
glycogen synthesis. Evidently, enzymes of gluconeogenesis were still up-regulated in cows 
from glucagon-treated groups after the end of glucagon administration, which caused extra 
glucose production. 
Plasma glucose concentration was increased during glucagon administration in a 
dosage-dependent manner (Figure 3A). The fact that glucagon administered to dairy cows 
causes an increase in blood glucose concentration agrees with the data of others (De Boer et 
al., 1986; Hippen et al., 1999a). The increase in plasma glucose concentration probably 
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occurred because of the activation of gluconeogenesis and/or repartitioning of glucose from 
the use in glycolysis. Glucagon administration did not increase plasma glucose concentration 
at the expense of glycogen degradation; there were no significant differences in liver 
glycogen concentration during glucagon administration (Figure 2). 
Plasma NEFA concentration declined substantially during the time of glucagon 
administration (Figure 3B), which is in agreement with our earlier published work (Hippen et 
al., 1999a). Our data support the findings of recent studies that suggest that glucagon has no 
direct effect on the rates of lipolysis in human subcutaneous adipose tissue in vivo (Bertin et 
al., 2001; Jensen et al., 1991), although some earlier studies indicated glucagon lipolytic 
effects in vivo and in vitro (Carlson et al., 1993; Perea et al., 1995). Moreover, changes in the 
insulin to glucagon ratio have no effect on the rates of lipolysis as shown in rats (Ubukata et 
al., 1996). Most likely, an increase in plasma insulin concentration after glucagon 
administration suppresses lipolysis (Elks and Manganiello, 1985) and/or enhances 
reesterification of NEFA in adipose tissue into TAG (Campbell et al., 1992). High blood 
glucose concentration (Figure 3A) can be responsible for enhanced antilipolytic action of 
insulin (Amer et al., 1983). 
There were no significant differences in the concentrations of plasma BHBA (Figure 
3C) and urinary acetone and acetoacetate (Figure 9) between either of the glucagon treated 
groups and the control group. The concentration of ketone bodies in plasma and urine 
however, tended to be higher in both the 15 mg/d of glucagon and control (saline) treatment 
groups. Plasma BHBA concentration in the control group was elevated around d 9 
postpartum probably because of high liver TAG (Figure lB) and low liver glycogen (Figure 
2) concentrations in those cows around that time (Drackley et al., 1992). Cows from the 15 
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mg/d glucagon treatment group also had elevated plasma BHBA concentrations, which might 
be explained by possible activation of liver carnitine palmitoyltransferase 1 (LCPT-1) by 
glucagon (Louet et al., 2002). Cows from the 7 .5 mg/d of glucagon treatment group did not 
have increased ketone body production, because glucagon dosage probably was not high 
enough to induce ketogenesis. 
Plasma urea tended to decrease in the glucagon-treated groups (Figure 3D), but the 
difference between the control and either of the glucagon-treated groups were not significant, 
which agrees with other studies (Hippen et al., 1999a, b ). The data provide indirect evidence 
that glucagon does not increase utilization of amino acids as gluconeogenic precursors. 
Around d 9 postpartum, plasma urea concentration was the lowest in the glucagon-treated 
groups and the highest in the control group. 
Glucagon injections caused a large increase in plasma insulin concentration, which 
was sustained until the end of the treatment period (Figure 4A). The data agree with earlier 
published work from our research group (She et al., 1999b). There was a steep rise in plasma 
insulin concentration above 900 pg/ml after d 8 postpartum in the 15 mg/d glucagon-
treatment group, which led to a substantial decrease in plasma NEF A. On the bases of 
Figures 3B and 4A, the reduction in plasma NEF A concentration below 400 µM can be 
achieved if plasma insulin concentration is above 900 pg/ml. Insulin inhibitory effect on 
lipolysis had been shown earlier. 
Plasma glucagon concentrations were around 4000 pg/ml and were not significantly 
different between the control group and either of the treatment groups throughout the study 
(Figure 4B). The fact that we did not observe any increase in plasma glucagon concentration 
after glucagon administration might be explained by a short half-life (5 min) of glucagon in 
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bovine blood (De Boer et al., 1986). Since we collected blood samples at 1 hr after glucagon 
administration, this indicates that most of the injected glucagon was degraded by that time. 
However, in comparison with the De Boer study, we used subcutaneous glucagon injections 
instead of intravenous application, which can produce lower glucagon peaks in blood after 
the injection and prolong slightly elevated glucagon concentrations in blood similar to what 
was observed in a human study (Muhlhauser et al., 1985). 
Milk production (Figure 5) was not affected by glucagon administration and was not 
significantly different between either of the glucagon-treated groups and the control group 
throughout the study. There was a rapid jump in milk production after parturition, which 
reached 27 kg/d by d 4 postpartum in all treatment groups. Then, milk production increased 
gradually in all treatment groups until the end of the study. 
Lactose concentration (Figure 4A) was not significantly different between either of 
the glucagon-treated groups and the control group throughout the study. However, lactose 
concentration in milk from 7.5 mg/d of glucagon treatment was observed to be slightly 
higher than in milk from the other treatment groups. Aside from variability among the cows, 
it is difficult to explain the cause of increase in lactose concentration in 7.5 mg/d of glucagon 
treatment group, but our data suggests that there is no direct relationship between blood 
glucose concentration and lactose biosynthesis. 
There were no significant differences in milk fat concentration between either of the 
glucagon-treated groups and the control group throughout the study (Figure 6B). Milk fat 
concentration was slightly higher in the control group around d 6 postpartum, and those 
control cows also exhibited higher plasma NEFA concentrations. In general, in cows with the 
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same milk production, milk fat concentration might be correlated positively with plasma 
NEF A concentration. 
Milk protein concentrations (Figure 6C) in all treatment groups declined during the 
first two weeks postpartum until it reached a plateau. There were no significant differences in 
milk protein concentrations between either of the glucagon-treatment groups and the control 
group, which disagrees with an earlier study from our group (Hippen et al., 1999a). Our data 
suggest that glucagon administration has no effect on milk protein concentration, which 
suggests the fact that glucagon does not facilitate the utilization of amino acids as 
gluconeogenic precursors during periparturient period. 
Milk urea concentration was significantly higher in the control group compared to 
glucagon-treated groups during the treatment period (Figure 6D), which indicates that 
treatment with glucagon may improve protein utilization. 
Feed intake of dairy cows (Figure 7) rose slowly throughout the treatment period, but 
feed intake was not significantly different between either of the glucagon-treated groups and 
the control group. Cows from the 7.5 mg/d of glucagon treatment group tended to have 
slightly higher feed intake around d 9 postpartum, which can be explained by lower ketone 
body concentration in blood and in urine around that time. Subcutaneous glucagon injections 
did not decrease feed intake as observed during intravenous glucagon administration (Hippen 
et al., 1999a). Surprisingly, increases in plasma glucose concentration caused by glucagon 
administration were not accompanied by increases in feed intake, which raises questions 
about (1) whether cows do not have enough gluconeogenic precursors around parturition 
(Gerloff, 2000) and (2) whether suppression of gluconeogenesic activity limits the use of 
glucose precursors available in feed (Rukkwamsuk et al., 1999a). We think that it is possible 
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that glucagon increases plasma glucose concentration not only by activating hepatic 
gluconeogenesis, but also by repartitioning glucose from use for energy production to milk 
production. Otherwise, it is difficult to explain why such a large increase in plasma glucose 
concentration after glucagon administration was not accompanied by increase in feed intake. 
Conclusions 
The results of our study show that subcutaneous injections of 15 mg/d of glucagon for 
14 d beginning at d 2 postpartum help to prevent fatty liver development in transition dairy 
cows. Glucagon administration at 7 .5 mg/d dosage shows a potential for fatty liver 
prevention, but possibly at a lower level. Subcutaneous glucagon injections increased plasma 
glucose and insulin concentrations, which decreased the rates of lipolysis from adipose tissue 
and possibly increased the rates of blood NEFA reesterification, causing a reduction in 
plasma NEFA concentration. As a result, liver TAG accumulation was prevented in the 15 
mg/d of glucagon treatment group. Glucagon administration at 7.5 mg/d dosage showed a 
potential for the prevention of liver TAG accumulation, but possibly at a reduced level. 
Increase in plasma glucose concentration in response to glucagon injections was mainly 
because of an activation of gluconeogenesis and possibly an increase in glucose 
repartitioning from utilization as an energy source. Glucagon did not cause liver glycogen 
depletion. There were no negative effects of glucagon administration on feed intake and milk 
production and composition of dairy cows. Glucagon injections decreased milk urea 
concentration and tended to decrease plasma urea concentration, which suggests a role of 
glucagon in improvement of protein utilization. There were no significant effects of glucagon 
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administration on the rates of ketogenesis. Considered together, these changes indicate that 
glucagon could be very useful tool for the control of fatty liver disease in transition dairy 
cows. 
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The objective of the current study was to test whether multiple subcutaneous 
glucagon injections of 7.5 and/or 15 mg/d dosages for 14 d beginning at d 2 postpartum 
could prevent the development of fatty liver disease in transition dairy cows. The idea of 
using glucagon for fatty liver prevention came from earlier work done in our research group 
(Hippen et al., 1999a), which demonstrated the use of 14-d intravenous infusion of glucagon 
to treat fatty liver and ketosis induced by feed restriction and diet supplementation with 1,3-
butanediol in lactating dairy cows. The results of the current study show that 14-d 
subcutaneous injections of 15 mg/d of glucagon beginning at d 2 postpartum prevent fatty 
liver development in transition dairy cows. Glucagon injections at 7 .5 mg/d dosage show a 
potential for fatty liver prevention. 
Subcutaneous glucagon injections increased plasma glucose and insulin and 
decreased plasma NEPA concentrations in transition dairy cows predisposed to fatty liver 
development postpartum because of overfeeding during the dry period. These beneficial 
effects of subcutaneous glucagon administration are thought to be responsible for decrease in 
liver total lipid and TAG concentrations and consequently fatty liver prevention in transition 
dairy cows. There were no significant effects of glucagon administration on plasma BHBA 
concentration. However, cows given the 15 mg/d of glucagon dosage tended to show 
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increase in plasma BHBA concentration around d 9 postpartum, which was similar to an 
increase in BHBA concentration in the control group around the same time. 
A mechanism by which glucagon is able to prevent fatty liver development is 
unknown. It is possible that glucagon indirectly inhibits the rate of lipolysis and stimulated 
uptake and reesterification of NEFA by adipose tissue because of increases in plasma insulin 
and glucose concentrations. Glucagon also can have an effect on depletion of liver TAG pool 
and/or increase of fatty acid utilization in liver by activating camitine palmitoyltransferase-1, 
which leads to increased ~-oxidation and/or ketogenesis. It seems like glucagon has no effect 
on the rates of VLDL synthesis and secretion from liver. This statement is supported 
indirectly by our data showing that glucagon has no effect on plasma TAG concentration. 
The effect of glucagon in this study was not confounded with the differences in body 
condition score between cows from different treatment groups, because there were no 
significant differences in body condition score between the cows from different treatment 
groups throughout the study. 
A use of glucagon as a preventive for fatty liver development did not cause any 
negative effects on feed intake, milk production, and milk composition of dairy cows, which 
makes glucagon a very useful tool for the disease prevention. Glucagon administration 
decreased milk urea concentration, which suggests that it has a beneficial effect on improving 
protein utilization in transition dairy cows. 
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Recommendations for Future Research 
The current study demonstrated that subcutaneous glucagon injections could be used 
for fatty liver prevention in transition dairy cows. However, there are still some questions 
that have to be answered in order to optimize the use of glucagon for fatty liver prevention or 
to come up with better ways to prevent and/or treat the disease. One of the questions is what 
is the best model for fatty liver disease in transition dairy cows? Earlier studies conducted in 
our research group used feed restriction and diet supplementation with 1,3-butanediol to 
induce fatty liver and ketosis in lactating dairy cows. Such an approach produced a relatively 
high incidence of fatty liver and ketosis in lactating dairy cows, but the etiology of naturally 
occurring fatty liver disease could be completely different from what was induced by those 
conditions. In the current study, we used diet supplementation with cracked corn to increase 
energy density of a dry cow ration during the last 30 d of a dry period to make cows more 
susceptible for fatty liver development postpartum because of over conditioning. It is 
believed that cows with higher body condition scores have a higher incidence of fatty liver 
disease. However, this approach was not very successful, because most of the cows in our 
study did not develop severe fatty livers. A possible explanation for a failure to develop a 
severe fatty liver disease in our study is that feed intake of dairy cows can start declining 
during the last month of a dry period, and, in this case, extra corn feeding might not be able 
to increase cows' body condition scores. Better models of fatty liver disease should be 
created in the future. One of the approaches that can be used is overfeeding of cows during 
the entire dry period or during the end of the lactation period plus during the dry period. Fatty 
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liver development is not only associated with high body condition scores of dairy cows but 
also could be developed by feeding large amounts of grain during a dry period. So, other 
alternatives than over conditioning should be considered for the disease development. 
More research has to be done to study the physiology of transition and lactating dairy 
cows. It would be very helpful to know what type of metabolic changes occur under normal 
and pathological conditions, because in the literature you can find contradictory statements 
about what is happening. For example, many authors claim that after calving transition dairy 
cows experience hypoglycemic conditions while the others suggest the opposite. None of 
them say what normal glucose concentration in blood of dairy cows should be around that 
time. That is why greater knowledge about the physiology of transition and lactating dairy 
cows would be very useful for data interpretation. Moreover, disagreements among results 
from different publications sometimes happen only because of differences in approaches 
used to analyze samples. Developing standardized assays would facilitate better data 
comparison across different studies. 
According to a current theory of fatty liver development in transition dairy cows, high 
blood NEFA concentration is highly correlated with postpartum disease incidence. Future 
studies of regulation of lipolysis in dairy cows can provide very useful information about the 
etiology and other possible ways of fatty liver treatment and prevention. 
Recent studies established a relationship between fatty liver and reproduction and 
between fatty liver and immune function of dairy cows. More studies have to be done to 
understand those relationships and to check whether glucagon administration has any effects 
on them. Some authors are trying to relate infertility problems seen in dairy cows to low 
blood insulin concentration around breeding time. More study of possible improvements of 
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reproductive performance of transition dairy cows related to the ability of glucagon 
administration to increase blood insulin concentration should be done. 
In addition, subcutaneous glucagon injections for 14 days are not practical for on 
farm use. Other alternatives such as a slow-release formulation of glucagon should be 
developed in the future and tested on transition dairy cows. 
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